Ferring Pharmaceuticals acquiring Gameto for up to $1.38bn
Swiss pharmaceutical group Ferring Pharmaceuticals has entered into a definitive agreement to acquire New York-based biotechnology company Gameto in a transaction valued at up to $1.38bn. The acquisition represents a major strategic expansion for Ferring in its core therapeutic area of reproductive medicine and maternal health. The transaction features a structured payment system that includes an upfront payment alongside substantial…
GE HealthCare acquires $945m Sofie Biosciences
Global MedTech and diagnostocs leader GE HealthCare has acquired Sofie Biosciences, a privately-held developer of radiopharmaceuticals and molecular imaging diagnostics, in a transaction valued at $945 million. The deal marks a major step forward in GE HealthCare’s strategy to expand its precision diagnostics business and secure greater operational control over the highly complex and time-sensitive radiopharmaceutical supply chain. Molecular imaging…
H. Lundbeck divests Italian pharma manufacturing subsidiary
Listed Danish pharmaceutical giant H. Lundbeck is divesting its Italian manufacturing subsidiary, Lundbeck Pharmaceuticals Italy, to Flamma, a privately owned Italian contract development and manufacturing organisation (CDMO). While the exact financial terms and transaction value have not been publicly disclosed, the deal marks a significant strategic realignment for both organisations. For Lundbeck, the divestment represents a deliberate effort to streamline…
Bayer sells oncology asset Stivarga for €375m
German global life science and pharmaceutical company Bayer has divested its established oncology asset Stivarga to the German pharmaceutical firm Grünenthal for a total consideration of up to €375m. The transaction, announced in September 2026, involves the transfer of rights for Stivarga, also known as regorafenib, which is a once daily oral multikinase inhibitor approved in more than 90 markets…
Merck signs $2.1bn SciBrunch Oncology Deal
Multinational biopharmaceutical company Merck has entered into an exclusive global licensing agreement with Chinese biotechnology firm SciBrunch Therapeutics for the development and commercialisation of SPR2015. SPR2015 is an investigational, preclinical, oral molecular glue inhibitor specifically engineered to target a mutation which is one of the most prevalent genetic alterations across major malignancies, including pancreatic, colorectal, and non small cell lung…
Archimed taking Esperion private in $1.1bn deal
Pharmaceutical company Esperion Therapeutics has announced it has entered into a definitive agreement to be acquired by the healthcare focused investment firm Archimed in a $1.10bn deal. Esperion, a commercial-stage biopharma group dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, has faced competitive pressures in the lipid lowering market and looking forward, will need to contend with…
Chiesi to buy KalVista in $1.9bn deal
Italian biopharmaceutical firm Chiesi Group has struck a definitive agreement to acquire listed KalVista Pharmaceuticals in an all-cash transaction valued at approximately $1.9bn. The transaction has secured unanimous approval from both corporate boards and is slated to close in the third quarter of 2026, subject to customary regulatory clearances and the tender of a majority of shares. Under the terms…
Gilead Expands oncology portfolio with $5bn Tubulis deal
Listed American biopharmaceutical company Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a privately held German biotechnology company, for a total potential consideration of $5bn. Under the terms of the deal, Gilead will provide an upfront cash payment of $3.15bn, with an additional $1.85bn tied to future contingent milestones. The transaction is expected to close in the…
Hygie31 acquires Spanish pharmacy group CentralFarma
French healthcare group Hygie31 has continued its rapid expansion strategy with the acquisition of prominent Spanish pharmacy group CentralFarma. The new structure will bring together more than 400 pharmacies and is expected to generate a turnover of over €600 million by the end of 2026. The move reinforces the group’s position as a leading consolidator in the pharmacy and health…
Novartis expands clinical pipeline with multi-billion dollar acquisitions
Novartis has expanded its clinical pipeline through the back to back acquisitions of Pikavation Therapeutics and Excellergy. The Swiss pharmaceutical giant is seeking to offset looming patent expiries for major brands such as Entresto and Promacta. The first transaction involves the acquisition of Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics, for $3bn. Under the definitive agreement, Novartis will pay $2bn…